Skip to content

Efficacy and feasibility study of the cognitive behavioral therapy program with psychoeducational videos for irritable bowel syndrome

Efficacy and feasibility study of the cognitive behavioral therapy program with psychoeducational videos for irritable bowel syndrome - An open label pilot study of the cognitive behavioral therapy with psychoeducational videos for irritable bowel syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000036327
Enrollment
20
Registered
2019-03-29
Start date
2016-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable bowel syndrome

Interventions

Cognitive Behavioral Therapy for Irritable Bowel Syndrome with previewing of psychoeducational video (Once a week, total 10 sessions)

Sponsors

National Center of Neurology and Psychiatry
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Persons diagnosed with irritable bowel syndrome based on the Rome III diagnostic criteria. 2. Those whose severity is moderate or severe (IBSSI-J score => 175). 3. Persons who can understand the purpose and content of this trial and give voluntary written informed consent.

Exclusion criteria

Exclusion criteria: 1. Person in whom organic disease is suggested by the presence of warning symptoms*. 2. Persons with a history of or concomitant inflammatory bowel disease, malignant tumor, or other bowel disease which could cause the current bowel symptoms. 3. Persons suffering from major psychiatric disease, such as psychotic disorders, bipolar disorder, substance abuse-related disorders, or eating disorders (persons with anxiety disorders and depression without suicidal ideation are not excluded) 4. Persons with antisocial personality disorders. 5. Persons observed to have significant suicidal ideation at screening. 6. Persons with another past or present psychiatric or physical disease that is likely to interfere with continuation and evaluation of the study. 7. Persons experiencing any other type of marked chronic pain. 8. Those taking narcotic analgesics. 9. Persons who anticipate difficulty attending 10 sessions as an outpatient during the 16-week CBT implementation period. 10. Those who have previously received structured individual CBT. 11. Those for whom verbal and written communication in Japanese is not possible 12. Pregnant or lactating women. 13. Any other person whom the principal investigator has determined to be unsuitable as a participant of the study. *Warning symptoms list. 1. Symptoms which first appeared after 50 years of age. 2. Any rectal bleeding that has not undergone sufficient medical investigation (excluding that caused by known hemorrhoids). 3. Diarrhea-predominant IBS in which no colonoscopy investigation has been conducted. 4. Unexplained weight loss without a change in eating habits. 5. Nocturnal symptoms sufficient to cause insomnia. 6. The presence of warning symptoms (anemia, inflammatory reactions, or fecal occult blood). 7. Persons with a family history of colon cancer in a first- or second-degree relative (grandparents, parents, siblings, or children).

Design outcomes

Primary

MeasureTime frame
1. The Japanese version of the irritable bowel syndrome-severity index (IBSSI-J)

Secondary

MeasureTime frame
1.Visceral sensitivity index (VSI) 2.IBS-Global Improvement Scale (IBS-GIS) 3.The Japanese version of the irritable bowel syndrome quality of life instrument (IBS-QOL-J) 4.Medical Outcome Study 36-item Short Form Health Survey (SF-36) 5.Beck Depression Inventory-Second Edition (BDI-2) 6.State Trait Anxiety Inventory (STAI) 7.Body vigilance Scale(BVS-J) 8.Effortful Control Scale for Adults 9.Cognitive Control Scale(CCS) 10.Presence or absence of avoidance behavior

Countries

Japan

Contacts

Public ContactTesuya Ando

National Center of Neurology and Psychiatry Department of Behavioral Medicine, National Institute of Mental Health

ando-t@ncnp.go.jp042-341-2711

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026